To investigate the effect of prior intravitreal anti–vascular endothelial growth factor (VEGF) injections on surgical and postoperative complication rates associated with cataract surgery in a nationally representative longitudinal sample of elderly persons.

Nonsyndromic myopia is increasing in frequency throughout the world, particularly high myopia (≥−6.0 diopters [D]), which is more associated with complications such as chorioretinal atrophy and retinal detachment.1 Although high myopia is sometimes clearly familial, only a limited number of genes have been associated with monogenic nonsyndromic myopia to date. Those associated with autosomal dominant nonsyndromic high myopia include zinc finger protein 644 (Online Mendelian Inheritance in Man [OMIM] *614159, ZNF644), SCO2 cytochrome c oxidase assembly protein (OMIM *604272, SCO2), solute carrier family 39 zinc carrier member 5 (OMIM *608730, SLC39A5), procollagen proline 2-oxoglutarate-4-dioxygenase alpha subunit isoform 2 (OMIM *600608, P4HA2), and coiled coil containing domain 111 (OMIM *615421, CCDC111).

Ocular surface squamous neoplasia (OSSN) represents a spectrum of diseases ranging from mild dysplasia to invasive squamous cell carcinoma. Ocular surface squamous neoplasia can be successfully managed with surgical excision or medical therapy. Interferon-α-2b (IFNα-2b) treatment recently has been established as a standard treatment option for OSSN, eliminating the need for surgical excision. However, approximately 15% of tumors do not respond to IFNα-2b therapy.1 It remains unclear which tumor-specific factors may affect treatment response or course after treatment.

To investigate the predictive factors associated with recurrence after anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD).

We report endothelial cell (EC) characteristics and central corneal thickness (CCT) from the Infant Aphakia Treatment Study (IATS) patients at the 5-year examination.

To compare results of the first 100 eyes of Descemet stripping automated endothelial keratoplasty (DSAEK) and Descemet membrane endothelial keratoplasty (DMEK) that were performed with a standardized technique at a single institution.